Dr. Iain Dukes has been the Chairman of the company since August 2016. Prior to this, he served as the Senior Vice-President and Head of Business Development and Licensing for Merck Research Laboratories; the Vice President of External Research & Development at Amgen, from August 2010 to August 2013; and the President, Chief Executive Officer, and a member of the Board of Directors, of Essentialis Therapeutics from 2007 to 2010. Currently, Dr. Dukes is a Venture Partner at OrbiMed Advisors LLC.

Dr. Frederick G. Vogt has been the Interim Chief Executive Officer and President, General Counsel of the company since June 2021. Prior tot his, he has worked at Morgan, Lewis & Bockius, and GlaxoSmithKline where he has held various leadership roles.

Mr. Jean-Marc Bellemin has been the Chief Financial Officer of the company since 2020. Prior to this role, he served as Executive Vice President of Finance and Chief Financial Officer of Gritstone Oncology. Previously, he served as Senior Vice President of Market Access, Business Solutions and Services of Actelion Pharmaceuticals US Inc.

Dr. Igor Bilinsky has been the Chief Operating Officer of the company since March 2021. Prior to this, he served as the Chief Business Officer of Oncternal Therapeutics; Chief Operating Officer of AmpliPhi Biosciences, and as General Manager and Senior Vice President at IGNYTA.

Mr. Friedrich Graf Finckenstein has been the Chief Medical Officer of Iovance Biotherapeutics since July 2019. Prior to this, he served as the Global Head of Oncology Translational Medicine at Roche Pharma Research and Early Development in Switzerland. He has also held several multiple clinical leadership roles at Bristol-Meyers Squibb Company.